TrialBlood advances2025

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma.

Inés Zugasti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.